SCHEMBL3830276

SCHEMBL3830276

CCC(O)C(O)(O)[C](O)O

nearest known ligand 0.50

Predicted protein targets (top 6)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.50
GRIN1 Q05586 4/20 0.31
GRIN2A Q12879 4/20 0.31
GRIN2D O15399 3/20 0.31
GRIN2C Q14957 3/20 0.31
GRIN2B Q13224 2/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2784984 0.80 TSHR (0.43) TSHR
SCHEMBL965732 0.77 CHRM1 (0.36) TSHR
SCHEMBL22443062 0.77 TSHR (0.46) TSHR
SCHEMBL934694 0.76 TSHR (0.40) TSHR
SCHEMBL17072311 0.73
SCHEMBL15349735 0.73
SCHEMBL760206 0.73
SCHEMBL28552922 0.73 TSHR (0.37) TSHRGRIN1GRIN2AGRIN2DGRIN2C
SCHEMBL6543364 0.71
SCHEMBL3812042 0.71

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113423470-B Cosmetic compounding agent, cosmetic, and method for producing same 三吉油脂株式会社 2024-07-09 CN disclosed
US-20240218254-A1 ADDITIVE FOR SURFACE ACTIVATION, AND EMULSION COMPOSITION USING SAME MIYOSHI OIL & FAT CO., LTD. (JP) 2024-07-04 US disclosed
WO-2024142526-A1 RUBBER COMPOSITION, LAMINATE, AND HOSE 横浜ゴム株式会社 2024-07-04 WO disclosed
US-20240201055-A1 CROSS-LINKED POLYMER, METHOD FOR SEPARATING SUBSTANCE, KIT FOR SEPARATING SUBSTANCE, KIT FOR TESTING FOR DISEASE, AND DEVICE FOR SEPARATING SUBSTANCE SANYO CHEMICAL IND LTD (JP) 2024-06-20 US disclosed
US-20240057587-A1 ORGANIC AMMONIUM SALT AND HYDROGEN-BONDING MATERIAL TREATMENT AGENT USING SAME MIYOSHI OIL & FAT CO.,LTD. (JP) 2024-02-22 US disclosed
EP-4317399-A1 CROSS-LINKED POLYMER, METHOD FOR SEPARATING SUBSTANCE, KIT FOR SEPARATING SUBSTANCE, KIT FOR TESTING FOR DISEASE, AND DEVICE FOR SEPARATING SUBSTANCE Sanyo Chemical Industries, Ltd. (JP) 2024-02-07 EP disclosed
CN-117295945-A Crosslinked polymer, method for separating substance, kit for detecting disease, and device for separating substance 三洋化成工业株式会社 2023-12-26 CN disclosed
CN-117203308-A Additive for making interface active and emulsifying composition using the same 三吉油脂株式会社 2023-12-08 CN disclosed
US-20230340356-A1 ADDITIVE OR COMPOSITION FOR IMPARTING LUBRICITY MIYOSHI OIL & FAT CO., LTD. (JP) 2023-10-26 US disclosed
EP-3766969-B1 BIOCATALYST SOLVENT USING IONIC LIQUID, AND BIOCATALYST SOLUTION CONTAINING BIOCATALYST AND SAID SOLVENT MIYOSHI YUSHI KK (JP) 2023-10-04 EP disclosed
US-20170029801-A1 BIOCATALYST SOLVENT USING IONIC LIQUID, AND BIOCATALYST SOLUTION CONTAINING BIOCATALYST AND SAID SOLVENT MIYOSHI OIL & FAT CO., LTD. (JP) 2017-02-02 US disclosed
EP-1585530-A4 BIOADHESIVE PHARMACEUTICAL COMPOSITIONS BARBEAU DONALD L (US) 2009-09-09 EP disclosed
US-7119079-B2 Bioadhesive pharmaceutical compositions B&G PARTNERS LLC 2006-10-10 US disclosed
EP-1585530-A2 BIOADHESIVE PHARMACEUTICAL COMPOSITIONS Barbeau, Donald L. (US) 2005-10-19 EP disclosed
WO-2004064754-A2 BIOADHESIVE PHARMACEUTICAL COMPOSITIONS BARBEAU DONALD L (US) 2004-08-05 WO disclosed
US-20040142880-A1 Bioadhesive pharmaceutical compositions B&G PARTNERS LLC 2004-07-22 US disclosed
US-6699848-B1 USEFUL FOR TREATMENT OF INFLAMMATORY BOWEL DISEASE B&G PARTNERS LLC 2004-03-02 US disclosed
WO-1997046543-A1 ACETYL DERIVATIVES OF THIAZOLES AND ANALOGUES THE UNIVERSITY OF WOLLONGONG (AU) 1997-12-11 WO disclosed
US-4046893-A ANALGESIC, ANTIPHLOGISTIC NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JA) 1977-09-06 US disclosed
US-3946012-A 6-L-dihydroxyethyl-2,4,7-trioxo-8-D-ribityl pteridine and process for producing the same NIPPON ZOKI PHARMACEUTICAL CO., LTD. (JA) 1976-03-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040142880-A1 Bioadhesive pharmaceutical compositions UGT1A10, APOL1, ALG1 TSHR 3298/4885GRIN1 2595/4885GRIN2A 3108/4885
US-20240057587-A1 ORGANIC AMMONIUM SALT AND HYDROGEN-BONDING MATERIAL TREATMENT AGENT USING SAME OR10J3, HCN4, CLIC4 TSHR 4611/4885GRIN1 506/4885GRIN2A 1523/4885
US-20240218254-A1 ADDITIVE FOR SURFACE ACTIVATION, AND EMULSION COMPOSITION USING SAME HAO2, NOTUM, FFAR2 TSHR 2408/4885GRIN1 1319/4885GRIN2A 1110/4885
US-20170029801-A1 BIOCATALYST SOLVENT USING IONIC LIQUID, AND BIOCATALYST SOLUTION CONTAINING BIOCATALYST AND SAID SOLVENT BCKDK, HACL2, HAO2 TSHR 4368/4885GRIN1 2425/4885GRIN2A 4364/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.